Effectiveness of Anti-Inflammatory Drugs for Preventing Pain Versus Treating Pain During Medical Abortion From 13 to 22 Weeks at Hung Vuong Hospital

Launched by LE THI KIEU TRANG · Nov 16, 2024

Keywords

ClinConnect Summary

This clinical trial at Hung Vuong Hospital is looking at how well non-steroidal anti-inflammatory drugs (NSAIDs) work for managing pain during medical abortions for pregnancies between 13 and 22 weeks. The main focus is to see if taking NSAIDs before pain starts (prophylactically) is more effective than taking them only when pain occurs (on-demand). Researchers will compare two groups of women: one group will receive NSAIDs as a preventive measure, while the other will take them only when they feel pain. They will also keep an eye on any side effects and how the abortion procedure goes.

To participate in this study, women must be at least 18 years old, in the right stage of pregnancy, and able to give informed consent. They should not have certain medical conditions that could complicate the abortion process. Participants can expect to be monitored for their pain levels and any side effects throughout the study. This trial aims to improve pain management during medical abortions, which could make the experience more comfortable for women.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Pregnant women aged 18 years or older.
• • No mental illness.
• • Gestational age between 13 and 22 weeks (based on the last menstrual period with a regular menstrual cycle and accurate recall of the last menstrual period, or based on a first-trimester ultrasound) with an indication of stillbirth, fetal malformation requiring termination, or voluntary abortion with counseling and understanding of the abortion procedure.
• • Willing to participate in the study.
• • Capable of reading and signing the informed consent form.
• • Able to provide personal information independently.
• Exclusion Criteria:
• • Medical conditions contraindicating medical abortion: bleeding disorders, anticoagulant use, moderate to severe anemia.
• • Cardiovascular conditions: heart failure, mitral valve stenosis, embolism, uncontrolled hypertension.
• • Other medical conditions: renal failure, adrenal gland disorders, severe asthma, liver and biliary diseases, glaucoma.
• • Active pelvic inflammatory disease or acute genital infections.
• • Previous uterine surgery.
• • Placenta previa or central placenta previa.
• • Uterine malformations.
• • History of allergy to NSAIDs, Mifepristone, or Misoprostol.
• • Unwillingness to participate in the study.